Cell and gene therapy

Start-up hopes to boost production of viral vectors for ATMPs
#AAV #Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Seed funding #Start-ups

Start-up hopes to boost production of viral vectors for ATMPs

New South African company NewBiologix has launched with the aim of developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. The company’s DNA-based platform is being developed to address manufacturing challenges associated with the production… Read More

#News #Start-up Zone

Cell and gene therapy
#Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Guide #Market reporting

Expert view: What’s next for cell and gene therapy?

Listen to this article on the DDW Podcast: What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? DDW's Megan Thomas finds out. Skills gap Bruce Levine, International Society for Cell & Gene Therapy (ISCT) Immediate Past President… Read More

#Exclusive Content #Trends & Analysis

Haematology
#Cell and gene therapy #CSL #Gene therapy #Haemophilia #MHRA #Phase III trial

First gene therapy for haemophilia B approved in Great Britain

CSL’s Hemgenix (etranacogene dezaparvovec) has been authorised as the first gene therapy for adults with severe and moderately severe haemophilia B (congenital Factor IX (FIX) deficiency) in Great Britain. It has been granted a marketing authorisation for patients without a history of FIX inhibitors by the UK Medicines and Healthcare… Read More

#News #Regulatory

#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug development #Drug discovery #GMP #Whitepaper

New whitepaper: Take a deep dive into cell therapy

Cell therapy research has never been more exciting with all of the research ongoing. Download this new white paper ‘Diving deep into cell therapy: An industry perspective’ to find out more. Learn more about the trends, insights, and perspectives from ACROBiosystems as a manufacturer of cell therapy… Read More

#News

ACROBiosystems DDW white paper
#Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Drug development #Drug discovery #GMP

Diving deep into cell therapy: An industry perspective

Cell therapy research has never been more exciting with all of the research ongoing. Learn more about the trends, insights, and perspectives from ACROBiosystems as a manufacturer of cell therapy reagents, including topics like: CAR-NK research Developing new CAR constructs Evaluation CAR expression detection Role of GMP Manufacturing in cell… Read More

#Resources

#Biopharmaceuticals #Cell and gene therapy #Life sciences

Can characterisation industrialise cell and gene therapy?  

The cell and gene therapy (CGT) market is rapidly expanding, and projections suggest it will reach over $90B by 2023. With a maturing clinical pipeline, many FDA-approved treatments are on the horizon. The biopharma industry must industrialise cell and gene therapy manufacturing to bring these life-saving therapies to a larger… Read More

#Exclusive Content #Opinion

Cell and gene therapies
#Advanced Therapies #Cell and gene therapy #Cell and Gene Therapy Catapult

New CGT process analytical technologies lab opens

The Cell and Gene Therapy Catapult (CGT Catapult) has opened a new laboratory in Stevenage, UK, which has been specifically designed and equipped to allow cell and gene therapy (CGT) developers to monitor and control their advanced therapy manufacturing processes in real-time, to improve product quality and safety while… Read More

#News

#Biopharmaceuticals #Cell and gene therapy #Covid-19 #Drug development

Overcoming inefficiencies to improve access to cell and gene therapy 

The cell and gene therapy (CGT) landscape has grown significantly in the past year. Between the 24 therapies already approved by the FDA1 and a marked increase in clinical trials, widespread accessibility to precision medicine feels within reach. Lauren Collison, PhD, Senior VP, Operations & Site Head, KBI Biopharma, reflects.  … Read More

#Exclusive Content #Opinion

Woman having an eye test
#Cell and gene therapy #Clinical trials #Gene therapy #Genetics / genomics #GenSight Biologics #Ophthalmology

Five-year data show gene therapy safe for ND4-LHON

GenSight Biologics has revealed pooled safety data from five clinical studies of lenadogene nolparvovec (Lumevoq), the largest cohort of ND4-LHON (Leber hereditary optic neuropathy) patients studied after gene therapy treatment. The data confirms the good overall safety profile of the product in terms of systemic and… Read More

#News

Genetic engineering
#Cell and gene therapy #CNS #Gene editing #Gene therapy #Genetics / genomics #Paediatrics #Stem cells

Gene therapy for ‘childhood dementia’ shows promise

An investigational gene therapy for Sanfilippo syndrome – which leads to a form of childhood dementia – has shown promising early results in a proof-of-concept study.  The study found that four out of five patients diagnosed with Sanfilippo have continued to gain cognitive skills in line with… Read More

#Editor's Choice #News

#Bioanalytics #Cell and gene therapy #Mergers and acquisitions #Waters Corporation

Waters acquires bioanalytics company Wyatt Technology

Waters Corporation has revealed it will acquire Wyatt Technology, a provider of light scattering and field-flow fractionation instruments, software, accessories, and services, for $1.36 billion.  The transaction is expected to close in the second quarter of 2023, subject to regulatory approvals and other closing conditions. … Read More

#News

#Cell and gene therapy #Drug development #Drug discovery #Webinar

Webinar: Opportunities for CGT in drug development

Hosted by DDW and supported by Benchling and BPS Bioscience, Cell and gene therapy: sustaining growth and maximising opportunities will be free to attend on February 17 at 8am PST / 11am EST / 4pm GMT / 5pm CET. Cell and gene therapies (CGT) are transforming the way diseases… Read More

#News

#AAV #Cell and gene therapy #Drug development #Drug discovery #Gene therapy #Immunology / Virology & Vaccines

Optimising AAV capsid purification through improved analytics

Listen to this article on the DDW Podcast: Svea Cheeseman, Refeyn, explains why better efficiency is needed to advance the production of viral vectors for use in gene therapies. Adeno-associated viruses (AAVs) are a promising, widely used vector for delivering gene therapies. As demand for AAV gene therapies increases, it is… Read More

#Exclusive Content

#Cell and gene therapy #Events

ESGCT Spring School 2023 registrations open

The European Society of Gene and Cell Therapy (ESGCT) is inviting eligible students to attend its Spring School, taking place at the Club Belambra “Les Criques” near Giens in the South of France, from 28 March to 31 March 2023.  ESGCT invites experts in the field of… Read More

#News

#Advanced Therapies #Cell and gene therapy #Cell culture #Drug development #Drug discovery #Whitepaper

Whitepaper: From bench to billions in cell and gene therapy

Download our new whitepaper ‘From bench to billions: A guide to facilitating scale-up of adherent cultures for cell and gene therapies’, brought you by Corning. Given the potential of emerging advanced therapies, market demand is likely to continue to grow. Generating the required quantity of cells efficiently becomes even more… Read More

#News

#Advanced Therapies #Cell and gene therapy #Cell culture #Drug development #Drug discovery

From bench to billions: A guide to facilitating scale-up of adherent cultures for cell and gene therapies

Given the potential of emerging advanced therapies, market demand is likely to continue to grow. Generating the required quantity of cells efficiently becomes even more challenging when the cells of interest are attachment-dependent, such as induced pluripotent stem cells (iPSCs). The choice of cell culture platform will have significant operational… Read More

#Resources